Drug intelligence / Profile preview

MBTC-MSC-EX0

Development stage: Unknown
Lead developer: Stemmedicare
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

MBTC-MSC-EX0 is an extracellular vesicle (EV)-based therapeutic developed by Stemmedicare for the topical treatment of atopic dermatitis. The drug candidate is derived from mesenchymal stem cells (MSCs) using Stemmedicare's proprietary non-immunogenic and immune-tolerized EV technology. This platform is designed to produce EVs that can modulate immune responses and promote tissue regeneration without triggering an adverse immune reaction. MBTC-MSC-EX0 is specifically formulated for topical administration to address skin inflammation and barrier dysfunction associated with atopic dermatitis. It is currently in Phase 1 clinical development.

Other names: MBTC-MSC-EX0 (Atopic Dermatitis Topical)

Beyond the preview

Go deeper on MBTC-MSC-EX0.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBTC-MSC-EX0.

Explore the full profile